Redeye comments on the slightly improved data, which are becoming mature, from the latest readout of...
Redeye comments on the preliminary results of the DignCap Delta study in Uruguay, stating that the f...
Redeye updates its estimates for the Q4 2023 report (due 1 February 2024) with lower sales estimates...
Redeye has revised its fair value range following Thomson Reuters’ cash offer of SEK50 per share.
Kommande fas IIb-studie Guard meddelade på måndagen att bolaget, efter återkoppling från FDA, planer...
Q-linea wins a 5-year public tender with a total value of EUR 0.
Q4'23 results due 2 February 23e EBITDA cut 1.4% and down 11.
ARR in line, new adj. EBITDA guidance 28% higher vs.
Aptahem genomför mellan den 15-29 januari år 2024 en företrädesemission om 34,6 MSEK.
Danmark och Sverige stödjer Ukraina med CV90 Danmark och Sverige har meddelat att de gemensamt komme...
Redeye comments on Thomson Reuters' increased public offer of SEK50 per share, which the independent...
NoHo Partners has sold its remaining stake (5.05m shares, 20.
Redeye comments on Arise’s production figure for the fourth quarter, which was released on Friday ev...
Redeye trims its forecasts for Q4 and 2024 slightly while retaining its Base Case.
Redeye comments on the announcement that Oskar Mühlbach will leave as CEO and that Raketech's founde...
Redeye views favorably the news that Lifeclean has entered into a new distribution partnership with ...
We comment on the termination in this note. Due to the early stage of the program, it does not influ...
Taaleri has today appointed Ilkka Laurila as group’s CFO.
Biosergen will conduct a new phase 1b study in patients with invasive fungal infections with its dru...
We expect stable performance in Q4 (due 8 Feb) Do not expect any contribution from new game Twilight...